Journal: bioRxiv

Article Title: CRlSPR/Cas9 screening revealed BlRC6-AS1 /BlRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer

doi: 10.1101/2025.10.01.679907

Figure Lengend Snippet: ( A ) Schematic of CRISPR-Cas9 screens: A lentiviral sgRNA library was transduced into PC3-Cas9 cells, which were then treated with DMSO or Abiraterone, respectively. After 28 days, sgRNAs were extracted for NGS. ( B ) Box plots displaying sgRNA distribution in the experimental groups from lncRNA CRISPR-Cas9 library: D0-DMSO (baseline), D28-DMSO (vehicle control), and D28-Abiraterone (treatment). ( C and D ) Volcano plots showing depleted (red; RRA Score ≤ 0.05, -log□FC ≥ 2) and enriched (blue; RRA Score ≤ 0.05, log□FC ≥ 2) genes. Screening analysis was performed with MaGeCK RRA. ( C ) Negative selection identified 523 abiraterone resistance-associated LncRNAs and 553 essential LncRNAs. ( D ) Positive selection revealed 717 LncRNAs associated with abiraterone sensitivity and 169 essential LncRNAs. ( E ) Venn diagram showed negatively selected genes from two comparisons: Abiraterone vs Control and Control vs D0. ( F ) MAGeCK analysis results displayed a ranking of genes based on their RRA scores. ( G ) Frequency distribution of log2 fold change for all sgRNAs (top) and log2 fold change of individual sgRNAs for representative candidates (bottom). Enriched and depleted sgRNA hits were indicated by red and blue vertical bars, respectively. ( H ) The RRA score distribution plot revealed the top 10 candidate LncRNAs associated with abiraterone resistance. ( I-N ) Cell viability assays in PC3 ( I-K ) and DU145 ( L-N ) cells treated with 0-70 μM abiraterone for 48h, following transduction with either control sgRNAs or sgRNAs targeting candidate lncRNAs: RP11-1079K10.3 ( I and L ), WWTR1-AS1 ( J and M ), and RP11-49K24.4 ( K and N ). Data are shown as the mean ± SD (n = 4 biological replicates). Data were analyzed by two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test ( I-N ).

Article Snippet: PC3-Cas9 cells (4×10 ) were transduced with either the Splicing-targeting CRISPR-Cas9 library for human lncRNAs (Addgene, Cat# 119977) or the Human genome-wide lentiviral CRISPR gRNA library version 1 (Addgene, Cat# 67989) at a multiplicity of infection (MOI) of 0.3, ensuring single gRNA integration per cell.

Techniques: CRISPR, Control, Selection, Transduction

Journal: Frontiers in Cell and Developmental Biology

Article Title: PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

doi: 10.3389/fcell.2020.598205

Figure Lengend Snippet: MEG3 Acts as an Upstream Regulator of MiR-216a and PD-L1. (A) MEG3 expression in TCGA EC tissues and normal tissues (ENCORI database). (B) qRT-PCR analysis of MEG3 expression in HEC-50, SPAC-1-L and EM cells. (C) MEG3 levels in HEC-50 cells transfected with MEG3 siRNA (or control siRNA), and in SPAC-1-L cells transfected with MEG3 expression vector (or control vector). (D) miR-216a expression was measured in HEC-50 cells transfected with MEG3 siRNA (or control siRNA), and in SPAC-1-L cells transfected with MEG3 expression vector (or control vector). (E) Wound-healing and invasion assays in HEC-50 cells transfected as indicated. (F) Wound-healing and invasion assays in SPAC-1-L cells transfected as indicated. (G) Examination of PD-L1 expression in HEC-50 cells following knockdown of MEG3, and in SPAC-1-L cells following overexpression of MEG3, using western blotting assays. (H,I) The mRNA expression of the indicated genes in HEC-50 cells following knockdown of MEG3, and in SPAC-1-L cells following overexpression of MEG3. VIM: Vimentin. ∗ P < 0.05.

Article Snippet: The PD-L1 cDNA expresion vector pCMV6-PD-L1 (PD-L1-vec, RC213071), the MCL-1 cDNA expression vector pCMV6-MCL-1 (MCL-1-vec, RC200521), the MEG3 expression vector pCMV6-MEG3 (MEG3-vec, SC105816) and the pCMV6 control vector (Ctr-vec, PS100001) were purchased from OriGene (Rockville, MD, United States).

Techniques: Expressing, Quantitative RT-PCR, Transfection, Control, Plasmid Preparation, Knockdown, Over Expression, Western Blot

Journal: Frontiers in Cell and Developmental Biology

Article Title: PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

doi: 10.3389/fcell.2020.598205

Figure Lengend Snippet: Model Summarizing the Role of MEG3, MiR-216a, PD-L1, and MCL-1 in Controlling the Proliferative and Invasive Potential of aggressive EC cells. The downregulation of MEG3 causes an elevation of miR-216a expression. By targeting the 3′-UTR of PD-L1 mRNA, miR-216a suppresses PD-L1 expression. PD-L1 serves as a tumor-suppressor to inhibit the proliferation, EMT and invasive potential of aggressive EC cells via repressing MCL-1 expression.

Article Snippet: The PD-L1 cDNA expresion vector pCMV6-PD-L1 (PD-L1-vec, RC213071), the MCL-1 cDNA expression vector pCMV6-MCL-1 (MCL-1-vec, RC200521), the MEG3 expression vector pCMV6-MEG3 (MEG3-vec, SC105816) and the pCMV6 control vector (Ctr-vec, PS100001) were purchased from OriGene (Rockville, MD, United States).

Techniques: Expressing

Journal: Blood

Article Title: An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma ∗

doi: 10.1182/blood.2023021991

Figure Lengend Snippet: lncRNA dropout CRISPR-Cas9 screen in MM cell lines. (A) Schematic representation of the CRISPR screening pipeline. (B) Spearman's correlation between pgRNA read count profiles (from DNA collected 30 days after transduction and selection of the library) across screen replicates = 0.85 and 0.88, respectively, for AMO-1 and ABZB, with color bars on top/left indicating cluster membership obtained via hierarchical clustering (complete distance method). (C) Representation of pgRNA abundance log fold changes (logFCs) in DNA collected 30 days after library transduction and selection vs plasmidic amounts for 3 groups of pgRNAs: nontargeting (negative controls [median logFC = 0.27 and 0.35, respectively, for AMO-1 and ABZB]), targeting ribosomal protein genes (control essential genes, median logFC = −0.68 and −0.43, with a logFC ≤−0.5, corresponding to a MAGeCK FDR ≤20%), and lncRNAs, across the 2 screens. Each point represents 1 of the 12 472 pgRNAs in the library with coordinates on the y-axis indicating the median logFC across screen replicates. (D) Gene-wise MAGeCK robust rank aggregation (RRA) scores for significant dependencies identified in the 2 screens at an FDR ≤20%. Top essential control genes, dependencies that are private to each cell line and shared across them (as per the color scheme) are highligted. (E) Number of significantly essential lncRNAs (at an FDR ≤20%) in the 2 screened cell lines and their overlap. MOI, multiplicity of infection.

Article Snippet: The human paired-guide RNA (pgRNA) library pool ( ) (Addgene number 89640) was used to perform the CRISPR-Cas9 screens (supplemental Materials and methods; , and ).

Techniques: CRISPR, Transduction, Selection, Control, Infection

Journal: Blood

Article Title: An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma ∗

doi: 10.1182/blood.2023021991

Figure Lengend Snippet: Functional validation of prioritized oncogenic lncRNA candidates. (A) RP11-350G8.5 and LINC00467 basal expression levels via quantitative real time PCR (qRT-PCR) in MM cell lines and peripheral blood mononuclear cells (PBMCs) from healthy donors (values are normalized to the expression of GAPDH). (B) Representative image of genomic PCR products before and after KO of LINC00467 and RP11-350G8.5 in AMO-1 cells, visualized on 1.5% agarose gels. On the right: Sanger sequence of the amplicons encompassing the CRISPR-targeted region. Blue rectangles highlight pgRNA binding sites, whereas colored lines refer to the schematic picture of the KO reported above the gel picture (on the left). (C) Representative image of flow cytometric monitoring of AMO-1 and ABZB cells transduced with a SCRAMBLE-GFP-CRISPR vector (dark gray) or LINC00467/KO-GFP-CRISPR vector (light blue) or RP11-350G8.5/KO- GFP-CRISPR vector (red). Light-gray curves represent the percentage of viable cells at day 0 (48 hours after lentiviral transduction) with overlapping colored curves at day 20. (D) Representative images of colony assay of AMO-1 and ABZB GFP-sorted cells, 15 days after plating, were generated using EVOS XL-Core microscope (Invitrogen by Thermo Fisher) (magnification ×10). (E) Number of colonies in 3 independent wells. (F) Dose-response curves 24 hours after treatment with bortezomib (1-10 nM). Percentage of viable cells ± standard deviation are normalized with respect to DMSO-treated cells (vehicle) for each experimental condition. Statistical differences were assessed across all plots via Student t test; ∗ P < .05, ∗∗ P < .01, and ∗∗∗ P < .001.

Article Snippet: The human paired-guide RNA (pgRNA) library pool ( ) (Addgene number 89640) was used to perform the CRISPR-Cas9 screens (supplemental Materials and methods; , and ).

Techniques: Functional Assay, Biomarker Discovery, Expressing, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Sequencing, CRISPR, Binding Assay, Transduction, Plasmid Preparation, Colony Assay, Generated, Microscopy, Standard Deviation

Journal: Blood

Article Title: An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma ∗

doi: 10.1182/blood.2023021991

Figure Lengend Snippet: RP11-350G8.5 putative oncogenic role: in vitro validation and preliminary data from in vivo models. (A) Flow cytometric monitoring of GFP expression in ABZB cells transduced with a SCRAMBLE-GFP-CRISPR negative control vector, an RPL8 /KO-GFP-CRISPR positive control vector (selected from Project Score [37]), and 2 GFP-CRISPR constructs encoding for 2 pgRNAs targeting RP11-350G8.5. Gray curves represent the percentage of viable cells at day 0 (48 hours after lentiviral transduction), while colored curves represent the percentage of viable cells at day 20. Bars on the right represent the fold change in percentage of GFP-expressing cells 20 days after target depletion against day 0. (B) Evaluation of IL-6R RNA expression level through quantitative real time PCR (qRT-PCR) on ABZB after transduction with SCRAMBLE vector or KO of RP11-350G8.5 with pgRNA#1 or pgRNA#2 or with a vector overexpressing RP11-350G8.5 (UP). (Data are normalized to the expression of GAPDH.) Statistics were obtained using multiple t -tests, resulting in no significant (ns) differences, as per the reported P values. (C) Flow cytometric monitoring of GFP in JJN.3 and NCI-H929 MM transduced cells, and percentage of GFP-positive cells is reported by overlapping curves referred to day 20 (colored curves) against day 0 (light gray curves). (D) Validation of RP11-350G8.5 KO in nontumoral cells, performed as described for A and C. (E) Representative images of RNA-FISH analysis. Nuclei are counterstained with DAPI (blue signal), whereas C3-fluorescein–conjugated GAPDH (green signal) has been used as cytoplasmic marker. Customly designed Stellaris probes targeting RP11-350G8.5 have been conjugated with 5-carboxytetramethylrhodamine (TAMRA) dye (red signal). Representative pictures acquired with a DMI6000-AF6000 Leica (Wetzlar, Germany) fluorescence microscope at magnification ×63 are reported, followed by specific regions of interest (ROIs), which are represented as enlarged images. (F) Dose-response curves 24 hours after treatment with bortezomib in AMO-1 cells overexpressing RP11-350G8.5 (1-10 nM). Statistics were analyzed using multiple t -tests (cutoff ∗ P < .05, ∗∗ P < .01). (G) In vivo imaging of engrafted ABZB cells. A total of 5 × 10 6 ABZB cells, which previously underwent highly efficient transduction (multiplicity of infection = 1) of RP11-350G8.5 KO-GFP or the SCRAMBLE vectors, were subcutaneously inoculated in mice (n = 2 per group). Images of tumors were acquired when the tumoral masses became palpable (identified as DAY 1), and at the end of the experiment (DAY 16, when tumors reached 2 cm in diameter). Both DAY 1 and DAY 16 were set up by considering SCRAMBLE mice, because SCRAMBLE cells have been faster to generate tumoral masses, due to their higher proliferative rate, and to grow up to 2 cm in diameter, with respect to KO cells. Tumors appear as yellow high-density signals on the right flank of the mice. Pictures were obtained with the IVIS (Perkin Elmer) system. (H) Tumor growth as mean measurement ± standard deviation (SD) across mice groups (n = 2). (I) Photographs of excised tumors were captured by a digital camera. (J) Weights of excised tumors, reported as mean ± SD across mice groups. Statistics were analyzed using multiple t -tests (cutoff: ∗ P < .05).

Article Snippet: The human paired-guide RNA (pgRNA) library pool ( ) (Addgene number 89640) was used to perform the CRISPR-Cas9 screens (supplemental Materials and methods; , and ).

Techniques: In Vitro, Biomarker Discovery, In Vivo, Expressing, Transduction, CRISPR, Negative Control, Plasmid Preparation, Positive Control, Construct, RNA Expression, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Marker, Fluorescence, Microscopy, In Vivo Imaging, Infection, Standard Deviation

Journal: Diagnostics

Article Title: A Pilot Study of Exploring miRNA–Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis

doi: 10.3390/diagnostics15192479

Figure Lengend Snippet: The distribution of levels of the target proteins between PDAC patients and healthy individuals. ( a ) ESR1, ( b ) HCFC1, ( c ) KCNA1, ( d ) CACNG3, and ( e ) EPC1. Differences between the groups were analyzed using the Mann–Whitney U test. Bars represent mean protein concentration, and error bars indicate standard deviation (mean ± SD). * p < 0.05 was considered statistically significant.

Article Snippet: Quantitative analysis of ESR1 (Human Estrogen Receptor Alpha, ESR1 ELISA Kit, E7871Hu), HCFC1 (Human Host Cell Factor C1, HCFC1 ELISA Kit, E0307Hu), KCNA1 (Human Voltage-Gated Potassium Channel Subunit Alpha-1, KCNA1 ELISA Kit, E1757Hu), EPC1 (Human Enhancer of Polycomb Homolog 1, EPC1 ELISA Kit, E1137529Hu), and CACNG3 (Human Voltage-Dependent Calcium Channel Subunit Gamma-3, CACNG3 ELISA Kit, E4572Hu) proteins in the serum samples of PDAC patients was performed using sandwich-format ELISA kits (BT Lab, Bioassay Technology Laboratory, Shanghai, China).

Techniques: MANN-WHITNEY, Protein Concentration, Standard Deviation

Journal: Diagnostics

Article Title: A Pilot Study of Exploring miRNA–Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis

doi: 10.3390/diagnostics15192479

Figure Lengend Snippet: Scatter plot matrix demonstrating the pairwise correlations among protein serum concentration levels of ESR1, HCFC1, KCNA1, CACNG3, and EPC1. The upper triangle of the matrix displays Pearson correlation coefficients (r) with corresponding p -values. Significant positive correlations were observed for each miRNA. * p < 0.05 and ** p < 0.001 were considered statistically significant.

Article Snippet: Quantitative analysis of ESR1 (Human Estrogen Receptor Alpha, ESR1 ELISA Kit, E7871Hu), HCFC1 (Human Host Cell Factor C1, HCFC1 ELISA Kit, E0307Hu), KCNA1 (Human Voltage-Gated Potassium Channel Subunit Alpha-1, KCNA1 ELISA Kit, E1757Hu), EPC1 (Human Enhancer of Polycomb Homolog 1, EPC1 ELISA Kit, E1137529Hu), and CACNG3 (Human Voltage-Dependent Calcium Channel Subunit Gamma-3, CACNG3 ELISA Kit, E4572Hu) proteins in the serum samples of PDAC patients was performed using sandwich-format ELISA kits (BT Lab, Bioassay Technology Laboratory, Shanghai, China).

Techniques: Concentration Assay

Journal: Diagnostics

Article Title: A Pilot Study of Exploring miRNA–Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis

doi: 10.3390/diagnostics15192479

Figure Lengend Snippet: Kaplan–Meier survival curves showing overall survival durations of patients based on the expression levels of target proteins. ( a ) ESR1, ( b ) HCFC1, ( c ) KCNA1, ( d ) CACNG3, and ( e ) EPC1.

Article Snippet: Quantitative analysis of ESR1 (Human Estrogen Receptor Alpha, ESR1 ELISA Kit, E7871Hu), HCFC1 (Human Host Cell Factor C1, HCFC1 ELISA Kit, E0307Hu), KCNA1 (Human Voltage-Gated Potassium Channel Subunit Alpha-1, KCNA1 ELISA Kit, E1757Hu), EPC1 (Human Enhancer of Polycomb Homolog 1, EPC1 ELISA Kit, E1137529Hu), and CACNG3 (Human Voltage-Dependent Calcium Channel Subunit Gamma-3, CACNG3 ELISA Kit, E4572Hu) proteins in the serum samples of PDAC patients was performed using sandwich-format ELISA kits (BT Lab, Bioassay Technology Laboratory, Shanghai, China).

Techniques: Expressing

Journal: Molecular Medicine Reports

Article Title: Alterations in the long non-coding RNA transcriptome in mesangial cells treated with aldosterone in vitro

doi: 10.3892/mmr.2017.7313

Figure Lengend Snippet: Reverse transcription-quantitative polymerase chain reaction quantification of microarray hybridization. (A) The relative expression level of lncRNAs BC168211, BC088254, AF336872, AY325162, BC168687, AF230638 and BC167085. (B) The relative expression levels of upregulated mRNAs, NM_001108598, NM_001109190 and NM_001101018, and (C) downregulated mRNAs, NM_019347, NM_177,962 and NM_0,011,08823. *P<0.05 vs. the control group. ALD, aldosterone; lncRNAs, long non-coding RNAs; MCs, mesangial cells.

Article Snippet: The cells were stored at −80°C and sent to the LncRNA Expression Microarray (Arraystar, Rockville, MD, USA).

Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Microarray, Hybridization, Expressing, Control

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: The experimental scheme of the study. The discovery cohort was composed of two TB patients and two age- and gender-matched healthy controls: one young male case-control pair and one senior female case-control pair. PBMC circRNA expression in the discovery cohort was profiled by both rRNA-depleted RNA-seq and a circRNA expression microarray. We aggregated circRNAs into pathway-level mechanisms using KEGG pathway definitions. Pathways with significant circRNA dysregulation were prioritized by performing a paired Wilcoxon signed-rank test between paired control and TB samples. A molecular signature was developed based on the dysregulated circRNAs within the prioritized pathways. This circRNA signature was further validated by qRT-PCR in a validation cohort with 11 healthy controls and 10 TB patients.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques: Control, Expressing, RNA Sequencing, Microarray, Quantitative RT-PCR, Biomarker Discovery

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: Landscape of PBMC circRNA expression. (a) A Venn diagram of the parental genes with circRNA transcripts among PBMCs, platelets, RBCs, and whole blood. (b) Distribution of log 2 -transformed TPM values of circular transcripts in PBMCs, platelets, RBCs, and whole blood. (c) The fraction of RNA-seq reads from coding linear, non-coding linear, and circular transcripts. (d) The cumulative distribution of TPM values of circular transcripts. A significantly increased circRNA TPM was observed in the TB patients compared with the healthy controls. The P -values were computed by the Kolmogorov-Smirnov test.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques: Expressing, Transformation Assay, RNA Sequencing

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: The KEGG pathways enriched by upregulated circRNAs. A paired Wilcoxon test was applied to identify the KEGG pathways enriched by dysregulated circRNAs in young and senior TB patients. (a) The correlation in Z -scores (computed by a paired Wilcoxon test) between young and senior case-control pairs. Each dot represents one KEGG pathway. The red points stand for the pathways with circular transcripts commonly upregulated in both young and senior TB patients. (b) Paired comparison of circRNA expression in the five prioritized KEGG pathways. (c) Comparison of the fraction of circRNA reads in the five pathways between healthy controls and TB patients.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques: Control, Comparison, Expressing

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: Technical validation of the five prioritized KEGG pathways using a circRNA expression microarray. Total RNA was treated with RNase R to remove linear transcripts and then subject to microarray hybridization.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques: Biomarker Discovery, Expressing, Microarray, Hybridization

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: The 7-circRNA signature.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques:

Journal: EBioMedicine

Article Title: Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

doi: 10.1016/j.ebiom.2017.12.007

Figure Lengend Snippet: The 7-circRNA signature. (a) Expression heatmap of the circRNAs within the 7-circRNA signature in the discovery cohort. The expression measured by both RNA-seq and circRNA microarray is displayed. (b) Comparison of the expression levels of the 7-circRNA signature between the healthy controls and TB patients in the validation cohort. The error bars represent the standard error of the mean. (c) Principal component analysis of the 7-circRNA signature. PC1: the first principal component; PC2: the second principal component. (d) Comparison of the circRNA-based TB index between the healthy controls and TB patients in the validation cohort. (e) The ROC curve of the TB index in distinguishing TB patients from healthy controls. The light blue area indicates the confidence interval of the ROC curve.

Article Snippet: The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression.

Techniques: Expressing, RNA Sequencing, Microarray, Comparison, Biomarker Discovery

Journal: Aging (Albany NY)

Article Title: Calycosin stimulates the proliferation of endothelial cells, but not breast cancer cells, via a feedback loop involving RP11-65M17.3, BRIP1 and ERα

doi: 10.18632/aging.202641

Figure Lengend Snippet: The effects of calycosin treatment on lncRNA profiles in HUVECs.

Article Snippet: Labeled cDNA was subjected to hybridization using the Human lncRNA OneArray Plus microarray (Phalanx Biotech Group, Taiwan), followed by scanning using an Agilent scanner (Agilent Technologies, USA).

Techniques: